203 related articles for article (PubMed ID: 21626029)
1. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
Geary SM; Lemke CD; Lubaroff DM; Salem AK
Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
[TBL] [Abstract][Full Text] [Related]
2. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
4. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
5. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
7. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
8. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
9. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
10. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
Houot R; Levy R
Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
[TBL] [Abstract][Full Text] [Related]
11. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells.
Chamoto K; Takeshima T; Wakita D; Ohkuri T; Ashino S; Omatsu T; Shirato H; Kitamura H; Togashi Y; Nishimura T
Cancer Sci; 2009 May; 100(5):934-9. PubMed ID: 19245434
[TBL] [Abstract][Full Text] [Related]
13. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
Front Immunol; 2018; 9():2319. PubMed ID: 30364187
[TBL] [Abstract][Full Text] [Related]
14. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
15. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
16. Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes.
Cheng WK; Wee K; Kollmann TR; Dutz JP
Clin Vaccine Immunol; 2014 Mar; 21(3):329-39. PubMed ID: 24391136
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
19. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.
Geary SM; Lemke CD; Lubaroff DM; Salem AK
PLoS One; 2013; 8(6):e67904. PubMed ID: 23840786
[TBL] [Abstract][Full Text] [Related]
20. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
